Salvia BioElectronics, a clinical-stage medical device company pioneering a novel neuromodulation therapy for people with resistant migraine, announced tha...
Eclipse Life Sciences, Inc., a privately held clinical-stage biopharmaceutical company developing next-generation therapies for retinal diseases, announced...
New designation expands on first Fast Track Designation in TMB-H colorectal cancer and is supported by monotherapy responses across m...
Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjug...
As demand for injectable therapies grows and manufacturing requirements become more complex, Vetter Pharma is expanding its global fill-finish network to...
GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced that it signed a Memorandum of Unders...
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new dr...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that...
Biopharma Boardroom speaks with Quentin Le Masne de Chermont, Head of Corporate Strategy and Business Development at Grünenthal Group, a...
Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that the U.S. Food and Drug Admin...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that...
In Cycle-1REF Phase 2 clinical trial, tovinontrine demonstrated substantial reduction in NT-proBNP, a biomarker for heart failure, in patients with HFrEF o...
Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral...
Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete sy...
© 2026 Biopharma Boardroom. All Rights Reserved.
